Document is current
Any future updates will be listed below
-
Authors
Ren, Zhenggang
Huang, Yao
Guo, Yabing
Hou, Ming-Mo
Wang, Wei
Kuang, Ming
Hao, Chunyi
Wang, Wentao
Zhang, Yanqiao
Song, Tianqiang
Dai, Chaoliu
Kuo, Hsing-Tao
Bao, Zinan
Zuo, Yunxia
Wang, Lei
Zhu, Fuxiang
Fan, Jia
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04948697 at ClinicalTrials.govDocuments that mention this clinical trial
AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma
https://doi.org/10.1007/s00262-026-04399-8
-
Funding
Funding for this research was provided by:
BeOne Medicines
- License Information
-
More Information
Article History
Received: 3 September 2025
Accepted: 13 April 2026
First Online: 28 April 2026
Declarations
:
: ZR has received consulting fees from AstraZeneca, MSD, and Roche; and has participated in data safety monitoring boards or advisory boards for Roche, AstraZeneca, and MSD. ZB, LW, and FZ are employees of BeOne Medicines; YZ is an employee of BeOne Medicines and reports stock or other ownership with BeOne Medicines. All remaining authors declare no potential conflicts of interest.
: Not applicable.
: This trial was approved by institutional review boards or independent ethics committees and conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Informed consent was obtained from each patient before any trial-specific procedures or treatment. The authors attest to the accuracy and completeness of the data and the fidelity of the trial to the protocol.
